Hologic Analysts Boost Their Forecasts After Q3 Results
Portfolio Pulse from Avi Kapoor
Hologic, Inc. (NASDAQ:HOLX) reported strong Q3 earnings, beating analyst estimates for both EPS and revenue. Despite issuing soft guidance for Q4, analysts have raised their price targets for the stock. JP Morgan, RBC Capital, and Needham all maintained their ratings while adjusting their price targets upwards.
July 30, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hologic reported strong Q3 earnings, beating estimates for both EPS and revenue. Despite issuing soft guidance for Q4, analysts have raised their price targets. JP Morgan raised its target to $95, RBC Capital to $82, and Needham maintained its $90 target.
Hologic's strong Q3 performance and the subsequent increase in price targets by multiple analysts suggest positive short-term momentum for the stock. The soft Q4 guidance may temper some enthusiasm, but the overall analyst sentiment remains bullish.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100